Published in J Control Release on August 27, 2004
Intramuscular delivery of DNA releasing microspheres: microsphere properties and transgene expression. J Control Release (2006) 0.93
The contribution of plasmid design and release to in vivo gene expression following delivery from cationic polymer modified scaffolds. Biomaterials (2009) 0.90
Investigation on magnetically controlled delivery of doxorubicin from superparamagnetic nanocarriers of gelatin crosslinked with genipin. J Mater Sci Mater Med (2010) 0.80
Preparation and characterization of magnetic poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) microspheres. J Mater Sci Mater Med (2007) 0.80
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta (2009) 1.94
Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol (2010) 1.81
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release (2010) 1.64
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Non-viral is superior to viral gene delivery. J Control Release (2007) 1.54
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci (2006) 1.46
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials (2006) 1.30
Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem (2010) 1.28
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc (2010) 1.27
Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol (2007) 1.24
A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano (2013) 1.22
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine (2012) 1.21
Development of non-viral vectors for systemic gene delivery. J Control Release (2002) 1.21
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther (2005) 1.19
Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther (2010) 1.17
Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther (2011) 1.15
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm (2005) 1.11
Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci (2010) 1.10
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev (2005) 1.10
The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm (2011) 1.08
A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother (2007) 1.08
Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release (2013) 1.08
HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release (2004) 1.08
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
LPD nanoparticles--novel nonviral vector for efficient gene delivery. Methods Mol Med (2002) 1.03
Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release (2008) 1.03
Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm (2010) 1.02
Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother (2005) 1.01
Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. Mol Ther (2005) 1.01
Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method? Pharm Res (2012) 1.00
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm (2012) 1.00
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials (2013) 0.99
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther (2013) 0.98
Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol (2004) 0.98
Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano (2014) 0.97
Recent advances in intravesical drug/gene delivery. Mol Pharm (2006) 0.97
Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol (2006) 0.96
The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials (2012) 0.94
Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol (2004) 0.93
Noninvasive gene delivery to the liver by mechanical massage. Hepatology (2002) 0.92
A syringe electrode device for simultaneous injection of DNA and electrotransfer. Mol Ther (2002) 0.92
Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol Ther (2005) 0.92
Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res (2004) 0.92
Controlled gene delivery system based on thermosensitive biodegradable hydrogel. Pharm Res (2003) 0.91
Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology (2003) 0.91
Non-immunostimulatory nonviral vectors. FASEB J (2004) 0.91
Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano (2014) 0.91
Lipid-protamine-DNA-mediated antigen delivery. Curr Drug Deliv (2005) 0.90
Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials (2013) 0.90
Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs (2008) 0.90
Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU Int (2007) 0.90
Recent advances in non-viral gene delivery. Adv Genet (2005) 0.89
Enhanced cutaneous gene delivery following intradermal injection of naked DNA in a high ionic strength solution. Mol Ther (2002) 0.89
Non-viral vector as vaccine carrier. Adv Genet (2005) 0.88
Thermosensitive hydrogel as a Tgf-beta1 gene delivery vehicle enhances diabetic wound healing. Pharm Res (2003) 0.88
Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm (2008) 0.88
Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology (2003) 0.87
Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release (2011) 0.87
Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors. Mol Ther (2007) 0.87
Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved. J Gene Med (2006) 0.87
Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv (2008) 0.86
Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunol Immunother (2011) 0.86
Mechanism of naked DNA clearance after intravenous injection. J Gene Med (2007) 0.86
Recent Advances in Non-viral Gene Delivery. Adv Genet (2005) 0.85
Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm (2010) 0.85
Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem (2012) 0.84
Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res (2004) 0.84
Mechanism of liver gene transfer by mechanical massage. Mol Ther (2004) 0.84
Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Mol Pharm (2006) 0.84
Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther (2002) 0.84
How does the cell overcome LCP nanoparticle-induced calcium toxicity? Mol Pharm (2013) 0.83
Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res (2002) 0.83
Cancer immunotherapy and nanomedicine. Pharm Res (2010) 0.83
Gene transfer to subdermal tissues via a new gene gun design. Hum Gene Ther (2003) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
Novel nonviral vectors target cellular signaling pathways: regulated gene expression and reduced toxicity. J Pharmacol Exp Ther (2007) 0.82
Smart polymeric nanoparticles for cancer gene delivery. Mol Pharm (2015) 0.82
Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release (2013) 0.81
The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. Int J Pharm (2008) 0.81
Intradermal injection of transforming growth factor-beta1 gene enhances wound healing in genetically diabetic mice. Pharm Res (2003) 0.81
Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine (Lond) (2010) 0.81
Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol Pharm (2011) 0.81
Cationic liposome-protamine-DNA complexes for gene delivery. Methods Enzymol (2003) 0.81